Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

1993-10-06

Study Completion Date

2008-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several studies have shown that specialized pacemaking devices (DDD pacing) can improve the symptoms associated with hypertrophic cardiomyopathy (HCM) in adults. In addition, studies have also shown that specialized pacemaking devices (DDD pacing) can improve conditions of HCM in children. However, growth of the body and organs, including the heart, is very rapid during childhood. Therefore the long-term effects of DDD pacing in children are unknown.

The purpose of this study is to examine the growth rate and nutrition of children with HCM. Due to this heart condition and the restrictions that are often placed on the child's activity level, children with HCM may grow at a slower rat and may have a greater tendency to be overweight.

Children participating in the study will have their growth rate and nutritional status measured before the study begins and throughout the course of the study.

Findings in this research study will not directly benefit the patients participating in it. However, information gathered as a result of this study may lead to improvements in the management of children with HCM in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle

NCT00001960

Hypertrophic Cardiomyopathy

COMPLETED PHASE2

Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy

NCT00001530

Cardiomyopathy, Hypertrophic

COMPLETED

Resynchronization Therapy in Young Patients With and Without CHD

NCT00208806

Dilated Cardiomyopathy Pediatric

COMPLETED

Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy

NCT03450252

Cardiomyopathy, Hypertrophic

COMPLETED NA

Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement

NCT01081093

Hypertrophic Cardiomyopathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several studies have shown that dual chamber (DDD) pacemaker therapy relieves LV outflow obstruction and improves symptoms in most adult patients with obstructive hypertrophic cardiomyopathy (HCM). It is however, uncertain whether DDD pacing will be efficacious in children with obstructive HCM, because of evolving cardiac morphology and increased LV hypertrophy and outflow obstruction associated with rapid body growth. We propose to monitor clinical progress, and cardiac morphologic and hemodynamic changes over several years following implantation of a DDD pacemaker in children who present with obstructive HCM between the ages of 5 to 15 years. Functional status, myocardial ischemia, arrhythmias, and LV outflow obstruction will be evaluated by exercise tests, echocardiography, thallium scintigraphy, Holter monitoring, electrophysiologic and cardiac catheterization studies. The results of pacemaker therapy will be compared with the findings in a cohort of young patients with obstructive HCM who elect not to be treated with DDD pacemaker.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paragon Pacemaker

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Children of either gender, aged 5 to 15 years.

Presence of LV hypertrophy and LV outflow obstruction.

Children of either gender, 5 to 20 years (children greater than 15 years will be included if there is access to reliable previous catheterization data).

Presence of LV hypertrophy and LV obstruction.

Exclusion Criteria

Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization.

Chronic atrial fibrillation.

Positive pregnancy test.

Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization.

Chronic atrial fibrillation.

Positive pregnancy test.

Minimum Eligible Age

5 Years

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No